Results 21 to 30 of about 118,941 (325)
Short-Term Effect of Sodium Glucose Co – Transporter 2 Inhibitors on Routine Laboratory Examinations
Journal of Contemporary Medicine, 2022 Backgroundː In this study, we aimed to examine the effect of Sodium Glucose Cotransporter 2 inhibitors (SGLT-2i) on routine laboratory test results at 12 weeks of follow-up among type 2 diabetes mellitus (T2D) patients using empagliflozin and ...
Osman İnan, Enes Şahiner
doaj +1 more source
Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice. [PDF]
Farmacja Polska, 2021 Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice. Type 2 diabetes mellitus, cardiovascular diseases and congestive heart failure are known to be a cause of growing ...
Beata Jacuś +3 more
doaj +1 more source
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk [PDF]
Diabetes Therapy, 2019 Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (CANVAS), a large randomized controlled trial (RCT) in ...
Anastasia Erythropoulou-Kaltsidou +2 more
openaire +2 more sources
A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitors
CPT: Pharmacometrics & Systems Pharmacology, 2023 Type 2 diabetes mellitus (T2DM) agent sodium‐glucose co‐transporter 2 (SGLT2) inhibitors show special benefits in reducing body weight and heart failure risks.
Xueting Yao +5 more
doaj +1 more source
Клинический разбор в общей медицине, 2021 The diabetic ketoacidosis (DKA) is the most frequent urgent condition in patients with diabetes mellitus which requires hospitalization and results to mortality. The most common causes of DKA are the presence of concomitant diseases in diabetic patients,
Diana Sh. Avzaletdinova +3 more
doaj +1 more source
International Journal of Molecular Sciences, 2021 Cardiovascular disease is the leading cause of morbidity and mortality in diabetes. Recent clinical studies indicate that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with diabetes.
W. Durante +2 more
semanticscholar +1 more source
Cardiovascular Diabetology, 2023 Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes.
Julia Hoehlschen +3 more
doaj +1 more source
Лечащий Врач, 2022 Impaired kidney function has a negative impact on the course of heart failure in both patients with and without diabetes mellitus. Therefore, the development and study of the effectiveness of methods for the treatment of chronic heart failure, especially
E. V. Kovalenko +2 more
doaj +1 more source
An emerging protagonist: Sodium Glucose Co-transporters (SGLTs) as a burgeoning target for the treatment of diabetes mellitus [PDF]
, 2012 Contemporary therapies to rationalize the hyperglycaemia in type 2 diabetes mellitus (T2DM) generally involve insulin-dependent mechanisms and lose their effectiveness as pancreatic b-cell function decreases to a greater extent. The kidney emerges out as
Danish Ahmed +3 more
core +2 more sources
SGLT2 Inhibitors for Nephrologists
European Medical Journal Nephrology, 2022 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides.
Mufti Baleegh-ur-Raheem Mahmood +1 more
doaj +1 more source